Clinical Deployment Strong potential for expansion within clinical and academic institutions that rely on cognitive assessment tools for Alzheimer’s disease, ADHD, and other cognitive disorders, offering a noninvasive solution that can complement existing workflows.

Global Research System already used in academic, clinical, pharmaceutical studies worldwide and even applied by the US Army, indicating high credibility and opportunity to upsell to research consortia, CROs, and defense medical programs.

Early HealthTech Small to mid-size neurodiagnostic players and startups in the sector align with Neuronetrix’s likely price points and features, suggesting partnership or channel opportunities with companies like OpenBCI and similar peers.

Market Focus Primary market centers on cognitive disorders with deficits in presentation; sales efforts can target neurology clinics, memory care centers, and ADHD specialty practices seeking objective cognitive measures.

Revenue Growth Current revenue scope ($1M–$10M) coupled with a scalable cognitive testing platform presents opportunities for multi-year licensing, enterprise trials, and expanded configurations to increase ARPU with institutional customers.